Azitra (NYSEAMERICAN:AZTR – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05), FiscalAI reports.
Azitra Trading Up 2.2%
Shares of Azitra stock traded up $0.00 during trading on Thursday, hitting $0.14. 459,604 shares of the company’s stock traded hands, compared to its average volume of 9,958,984. The business has a 50-day simple moving average of $0.16 and a 200-day simple moving average of $0.20. Azitra has a 1 year low of $0.10 and a 1 year high of $1.40.
Azitra Company Profile
Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.
The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.
Featured Stories
- Five stocks we like better than Azitra
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
